Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
- @IpsenGroup RT @FondationIpsen: many attendees to Bruce Mc Ewen's award lecture on stress estrogens and brain plasticity at #ECE #endocrinology https:/…
- @IpsenGroup RT @FondationIpsen: Bruce McEwen will be awarded of the Fondation IPSEN endocrine regulations prize today at 9am #ECE #Endocrinology : http…
- @IpsenGroup RT @ElsaRiveHealth: Boston Paris Biotech Summit : Meet & Hear from the Majors Industry Players at @institutpasteur @BF_healthcare @FranceBi…
- @IpsenGroup RT @ElsaRiveHealth: Advice for Success : Thank you David Meek CEO of @IpsenGroup for mentioning #Medstartup Program by the @GalienFdn & @bu…
IPSEN AT A GLANCE
Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.58 billion in 2016. Our ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Our fields of expertise cover oncology, neurosciences and endocrinology.
RESEARCH & DEVELOPMENT
Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.